

Treating recurrent migraine by closing a patent foramen ovale using a device inserted via the groin

NICE 'HealthTech guidance' advises the NHS on when and how new procedures can be used in clinical practice.

This leaflet is about when and how closing a patent foramen ovale (PFO) using a device inserted via the groin can be used in the NHS to treat people with recurrent migraine. It explains guidance (advice) from NICE (the National Institute for Health and Clinical Excellence).

This HealthTech guidance makes recommendations on the safety of a procedure and how well it works. An interventional procedure is a test, treatment or surgery that involves a cut or puncture of the skin, or an endoscope to look inside the body, or energy sources such as X-rays, heat or ultrasound. The guidance does not cover whether or not the NHS should fund a procedure. Decisions about funding are taken by local NHS bodies (primary care trusts and hospital trusts) after considering how well the procedure works and whether it represents value for money for the NHS.

NICE has produced this guidance because there is not a lot of information yet about how well the procedure works, how safe it is and which patients will benefit most from it.

This leaflet is written to help people who have been offered this procedure to decide whether to agree (consent) to it or not. It does not describe recurrent migraine or the procedure in detail – a member of your healthcare team should also give you full information and advice about these. The leaflet includes some questions you may want to ask your doctor to help you reach a decision. Some sources of further information and support are on page 7.

What has NICE said?

There is not much good evidence about how well this procedure works. The evidence on safety shows that there is a small risk of serious complications, including movement of the device which may enter the circulation. If a doctor wants to close a PFO using a device inserted via the groin to treat recurrent migraine, they should make sure that extra steps are taken to explain the uncertainty about how well it works, as well as the potential risks of the procedure, including the possibility of serious complications. This should happen before the patient agrees (or doesn't agree) to the procedure. The patient should be given this leaflet and other written information as part of the discussion. There should also be special arrangements for monitoring what happens to the patient after the procedure.

A team of healthcare professionals including a neurologist or other headache specialist and an interventional cardiologist should decide which patients should have this procedure. It should only be offered to patients who are severely affected by recurrent migraine which has not responded to other treatments.

The procedure should only be carried out by a cardiologist and supporting team with specific training in the procedure, and in units with access to emergency heart surgery in case of complications.

NICE has encouraged further research into this procedure and may review it if more evidence becomes available.

This procedure may not be the only possible treatment for recurrent migraine. Your healthcare team should talk to you about whether it is suitable for you and about any other treatment options available.

Treating recurrent migraine by closing a PFO using a device inserted via the groin

The medical name for this procedure is ‘percutaneous closure of patent foramen ovale for recurrent migraine’.

The procedure is not described in detail here – please talk to your headache specialist and cardiologist for a full description.

Migraine is a severe headache often accompanied by other symptoms such as light sensitivity and is usually treated by medication.

The foramen ovale is a small hole between the two upper chambers of the heart that is present during development in the womb. It normally closes after birth but in some people it remains open (patent). This usually causes no symptoms, but tests may show abnormal movement of blood between the normally separate heart chambers. It has been found that closing the hole may help to treat recurrent migraine, although it is not known why.

The procedure is performed using a local anaesthetic and sedation, or general anaesthesia. A guidewire and catheter are inserted through a vein in the groin into the heart and through the PFO using imaging guidance. A device is then inserted via the catheter, closing the hole.

What does this mean for me?

NICE has decided that there are uncertainties about how well this procedure works, and there is a small risk of serious complications. This does not mean that the procedure should not be done, but that your doctor should fully explain what is involved in having the procedure and discuss the possible benefits and risks with you. You should only be asked if you want to agree to this procedure after this discussion has taken place. You should be given written information, including this leaflet, and have the opportunity to discuss it with your doctor before making your decision. NICE has also decided that more information is needed about this procedure. Your doctor may ask you if details of your procedure can be used to help collect more information about this procedure. Your doctor will give you more information about this.

You may want to ask the questions below

- What does the procedure involve?
- What are the benefits I might get?
- How good are my chances of getting those benefits? Could having the procedure make me feel worse?
- Are there alternative procedures?
- What are the risks of the procedure?
- Are the risks minor or serious? How likely are they to happen?
- What care will I need after the procedure?
- What happens if something goes wrong?
- What may happen if I don't have the procedure?

You might decide to have this procedure, to have a different procedure, or not to have a procedure at all.

Summary of possible benefits and risks

Some of the benefits and risks seen in the studies considered by NICE are briefly described below. NICE looked at 14 studies on this procedure. Some of the studies looked at patients who had the procedure for reasons other than recurrent migraine.

How well does the procedure work?

In 5 studies including a total of 1283 patients who had the procedure for a number of different conditions, the PFO was immediately closed in 1268 patients (99%).

In a study of 147 patients, 3 out of 74 who had the procedure and 3 out of 73 who had a dummy procedure reported that they had experienced no further migraines in the 6 months after surgery. The study also reported that there was no difference between the 2 groups of patients in terms of severity, frequency or the number of days on which they experienced migraines in the 6 months after surgery.

In a study of 86 patients treated either by the procedure or medication, all had experienced a reduction in migraine severity 2 and half years after surgery.

As well as looking at these studies, NICE also asked expert advisers for their views. These advisers are clinical specialists in this field of medicine. The advisers said that key indicators of success are complete closure of the PFO, and frequency and severity of migraine.

Risks and possible problems

In a study of 280 patients, a collection of blood around the heart which interfered with its pumping (cardiac tamponade) was reported in 2 patients who both required further surgery.

The device used to close the PFO caused a tear in a large blood vessel of the heart requiring emergency surgery in 1 patient. The device fell out and entered the circulation in 7 of a total of 992 patients in 2 studies (the device was removed from patients in 1 of these studies, no further details were given for the second).

Abnormal heart rhythm during or after surgery was reported in 13 of 95 patients in 2 studies of a total of 213 patients.

As well as looking at these studies, NICE also asked expert advisers for their views who said that in theory, a problem with the heart valves could occur.

More information about migraine and PFO

NHS Choices (www.nhs.uk) may be a good place to find out more. Your local patient advice and liaison service (usually known as PALS) may also be able to give you further information and support. For details of all NICE guidance on PFO, visit our website at www.nice.org.uk

About NICE

NICE produces guidance (advice) for the NHS about preventing, diagnosing and treating different medical conditions. The guidance is written by independent experts including healthcare professionals and people representing patients and carers. They consider how well an interventional procedure works and how safe it is, and ask the opinions of expert advisers. This guidance applies to the whole of the NHS in England, Wales, Scotland and Northern Ireland. Staff working in the NHS are expected to follow this guidance.

To find out more about NICE, its work and how it reaches decisions, see www.nice.org.uk/aboutguidance

This leaflet is about 'percutaneous closure of patent foramen ovale for recurrent migraine'. This leaflet and the full guidance aimed at healthcare professionals are available at www.nice.org.uk/guidance/HTG242

You can order printed copies of this leaflet from NICE publications (phone 0845 003 7783 or email publications@nice.org.uk and quote reference N2385). The NICE website has a screen reader service called Browsealoud, which allows you to listen to our guidance. Click on the Browsealoud logo on the NICE website to use this service.

We encourage voluntary organisations, NHS organisations and clinicians to use text from this booklet in their own information about this procedure.

National Institute for Health and Clinical Excellence

MidCity Place, 71 High Holborn, London, WC1V 6NA; www.nice.org.uk

Information about NICE HealthTech guidance 242

ISBN 978-1-4731-8261-5

N2385 1P Dec 10

© National Institute for Health and Clinical Excellence, 2010. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.